Nektar Therapeutics
NKTR
140 hedge funds and large institutions have $183M invested in Nektar Therapeutics in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 17 closing their positions.
691% more call options, than puts
Call options by funds: $182K | Put options by funds: $23K
81% more capital inflows, than outflows
Capital inflows: $15.2M | Capital outflows: $8.39M
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
5% more funds holding
Funds holding: 133 → 140 (+7)
2.86% more ownership
Funds ownership: 73.61% → 76.47% (+2.9%)
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Eventide Asset Management
Boston,
Massachusetts
|
+$2.38M |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
+$1.73M |
| 3 |
Woodline Partners
San Francisco,
California
|
+$1.41M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.21M |
| 5 |
BlackRock
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
-$2.48M |
| 2 |
Morgan Stanley
New York
|
-$923K |
| 3 |
GSA Capital Partners
London,
United Kingdom
|
-$911K |
| 4 |
Two Sigma Investments
New York
|
-$567K |
| 5 |
Two Sigma Advisers
New York
|
-$426K |
NKTR Hedge Fund Activity: Q3 2024 in Review
140 of the 6,989 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2024, worth a combined $183M — up 8.9% from $168M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NKTR positions and 17 closed out — a net gain of 7 holders — while 37 added to existing stakes and 34 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $2.38M. The largest seller was Deep Track Capital, cutting an estimated $2.48M.
- 140 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2024, up from 133 in Q2 2024.
- Funds reported $183M of Nektar Therapeutics stock for Q3 2024, up 8.9% quarter-over-quarter.
- 24 funds opened new Nektar Therapeutics positions in Q3 2024 and 17 closed out, a net change of +7 holders.
- The largest Nektar Therapeutics buyer in Q3 2024 was Eventide Asset Management, an estimated $2.38M added.
- The largest Nektar Therapeutics seller in Q3 2024 was Deep Track Capital, an estimated $2.48M sold.
Based on aggregated 13F filings for Q3 2024.